Literature DB >> 23336676

Peripheral neuropathy in patients with myotonic dystrophy type 1.

Stojan Peric1, Vidosava Rakocevic Stojanovic, Ana Nikolic, Aleksandra Kacar, Ivana Basta, Sanja Pavlovic, Dragana Lavrnic.   

Abstract

OBJECTIVES: To assess the frequency and type of peripheral neuropathy (PNP) in patients with myotonic dystrophy type 1 (DM1), as well as to identify factors that may be associated with this abnormality.
METHODS: This study comprised 111 adult patients with DM1. Nerve conduction study was performed on sural, peroneal and median nerves of both limbs.
RESULTS: PNP was somewhat more frequent in DM1 patients with glucose intolerance and diabetes mellitus (66.7 vs. 33.7%, P = 0.05). In DM1 patients with no glucose intolerance, diabetes mellitus and thyroid dysfunction, the most frequent type of PNP was demyelinating (70.0%) and motor (83.3%). PNP was more frequent in males (45.7 vs. 20.9%, P<0.05). Patients with PNP were older (43.7±7.3 vs. 39.6±9.6 years, P<0.05) and had a longer duration of DM1 compared to those without PNP (18.6±9.9 vs 12.7±8.3 years, P<0.01). DM1 patients with PNP had a higher body mass index) (24.9±5.5 vs. 22.4±4.2 kg/cm2, P<0.05), higher triglycerides (3.1±3.3 vs. 1.8±0.8 mmol/l, P<0.01), total cholesterol (6.2±1.4 vs. 5.4±1.1 mmol/l) and LDL cholesterol (4.3±1.2 vs. 3.4±1.0, P<0.05). Achilles reflexes were absent in 76.9% patients with PNP and in 51.9% patients without PNP (P<0.05). Patellar reflexes and muscle strength were similar in both groups (P>0.05).
CONCLUSIONS: PNP was present in one-third of DM1 patients. The most common type was motor and demyelinating PNP. Our results suggest the association between the presence of peripheral nerve impairment in DM1 and male gender, age, duration of disease and certain metabolic parameters.

Entities:  

Mesh:

Year:  2013        PMID: 23336676     DOI: 10.1179/1743132812Y.0000000144

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  8 in total

1.  Cell type-specific abnormalities of central nervous system in myotonic dystrophy type 1.

Authors:  Masayuki Nakamori; Hiroshi Shimizu; Kotaro Ogawa; Yuhei Hasuike; Takashi Nakajima; Hidetoshi Sakurai; Toshiyuki Araki; Yukinori Okada; Akiyoshi Kakita; Hideki Mochizuki
Journal:  Brain Commun       Date:  2022-06-10

Review 2.  Myotonic Dystrophy Type 1 Management and Therapeutics.

Authors:  Cheryl A Smith; Laurie Gutmann
Journal:  Curr Treat Options Neurol       Date:  2016-12       Impact factor: 3.598

Review 3.  Brain pathology in myotonic dystrophy: when tauopathy meets spliceopathy and RNAopathy.

Authors:  Marie-Laure Caillet-Boudin; Francisco-Jose Fernandez-Gomez; Hélène Tran; Claire-Marie Dhaenens; Luc Buee; Nicolas Sergeant
Journal:  Front Mol Neurosci       Date:  2014-01-09       Impact factor: 5.639

4.  Myotonic Dystrophy Type 1 with Syringomyelia in a Young Patient.

Authors:  Xiao-Lin Yu; Ru-Zhen Jia; Pei-Yan Shan; Chuan-Zhu Yan; Ai-Fen Liu
Journal:  Chin Med J (Engl)       Date:  2016-02-20       Impact factor: 2.628

5.  Pain in adult myotonic dystrophy type 1: relation to function and gender.

Authors:  Gro Solbakken; Sissel Løseth; Anne Froholdt; Torunn D Eikeland; Terje Nærland; Jan C Frich; Espen Dietrichs; Kristin Ørstavik
Journal:  BMC Neurol       Date:  2021-03-04       Impact factor: 2.474

Review 6.  Metabolic Alterations in Myotonic Dystrophy Type 1 and Their Correlation with Lipin.

Authors:  Tiago Mateus; Filipa Martins; Alexandra Nunes; Maria Teresa Herdeiro; Sandra Rebelo
Journal:  Int J Environ Res Public Health       Date:  2021-02-12       Impact factor: 3.390

Review 7.  Neuromuscular Development and Disease: Learning From in vitro and in vivo Models.

Authors:  Zachary Fralish; Ethan M Lotz; Taylor Chavez; Alastair Khodabukus; Nenad Bursac
Journal:  Front Cell Dev Biol       Date:  2021-10-27

Review 8.  Core Clinical Phenotypes in Myotonic Dystrophies.

Authors:  Stephan Wenninger; Federica Montagnese; Benedikt Schoser
Journal:  Front Neurol       Date:  2018-05-02       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.